NCT00108446

Brief Summary

This study is being done to collect new information on irritable bowel syndrome, a disease that causes abdominal pain that does get better with treatment or keeps coming back ("chronic"). To better understand what causes the irritable bowel syndrome, we are studying drugs used to treat pain, dextromethorphan, naloxone, fentanyl, and lidocaine. We will study the effects these drugs have on experimental pain. Dextromethorphan is used in non-prescription cough syrups. Naloxone is used for reversing the effects of narcotic pain relievers. Fentanyl is a narcotic used to treat pain and to make a person relaxed (sedated) before anesthesia. The purpose of this study is to see what kinds of pain are affected by these drugs in persons who have irritable bowel syndrome and persons who do not have this problem.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Oct 2003

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 15, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 18, 2005

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2006

Completed
Last Updated

January 21, 2009

Status Verified

May 1, 2007

First QC Date

April 15, 2005

Last Update Submit

January 20, 2009

Conditions

Keywords

Irritable Bowel Syndromevisceral hypersensitivitycutaneous hypersensitivitylidocaine

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Premenopausal women age 18 years or older OR healthy controls
  • Patients with diarrhea predominant IBS that meet the \*Rome II criteria
  • The subject must speak English and be able to give informed consent
  • All subjects will be tested in the follicular stage of the menstrual cycle as determined by menstrual history and urine testing
  • Functional Bowel Disorder Severity Index score of none (0 points) for controls and moderate (37-110 points) for IBS patients
  • Normal baseline EKG

You may not qualify if:

  • Subject is currently participating in another research protocol that could interfere or influence the outcome measures of the present study
  • Subject is unable to give informed consent
  • A medical condition that would contraindicate the use of lidocaine (i.e., amide allergy) or a previous history of an abnormal EKG
  • Subjects with a positive pregnancy test will be excluded because the use of lidocaine is contraindicated in pregnant women
  • Subject is currently taking pain medications, NSAIDs, antihistaminics, antidepressants (tricyclic antidepressants \[TCA\]/selective serotonin reuptake inhibitors \[SSRI\]), anti-convulsants, migraine medications, and cough suppressants
  • Presence of systemic disease: diabetes, thyroid disease, gastrointestinal/liver disease (other than IBS), collagen vascular disease, focal or systemic neurological disease, malignancy, seropositive for HIV, or documented psychiatric disorders
  • Presence of any chronic pain condition including fibromyalgia
  • Subject drinks \> 2 oz. alcohol/day on a regular basis
  • Presence of large, palpable hemorrhoids on digital rectal exam that may alter rectal lidocaine adherence to rectal wall
  • Abnormal baseline EKG

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Malcom Randall VAMC

Gainesville, Florida, 32608, United States

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome

Interventions

DextromethorphanNaloxoneFentanylLidocaine

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsPiperidinesHeterocyclic Compounds, 1-RingAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
FED

Study Record Dates

First Submitted

April 15, 2005

First Posted

April 18, 2005

Study Start

October 1, 2003

Study Completion

March 1, 2006

Last Updated

January 21, 2009

Record last verified: 2007-05

Locations